Nicholas Saraceno, Editor

Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.

Cohort study aims to determine whether or not these regulatory changes in state government have helped reverse opioid mortality rates.

A non-randomized control trial investigates whether older adults with multiple chronic conditions can benefit by receiving more specialized services.

As technology continues to advance, investigators explore the legal protocol for how to handle AI-responsible injuries.

Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).

Study describes how a game theoretic model can successfully analyze how adoption of blockchain technology can reveal quality information.

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

JAMA Health Forum details the DSCSA and stresses the value of protecting the pharmaceutical supply chain from adulterated products.

Cureus report discuss the value of AI, but the medical community must remain aware of privacy pitfalls.

Morgan Company report makes the case for expanding coverage for GLP-1s beyond diabetes treatment and into the weight loss class, but are employers on board?

Study investigates the gaps in access to this service, and how internet service impacts telehealth use.

Review article explores the latest developments surrounding expression and purification strategies.

Analysis reveals how QbTest is used to measure the effectiveness of ADHD drugs.

Electronic health record messaging network found to improve communication and lead to better medication adherence.

Study examines the parallels between doctorate students and the US population.

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

Over the past year, Pharma Commerce’s digital coverage featured a variety of subject matters, ranging from how to calculate 340B prices, to the future of pharmacy.

The most popular pieces pertaining to the supply chain featured ADMs, vaccine supply chains, and wholesalers.

Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.

This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.

Camille Lee discusses the impact of commercial availability of Bimzelx for the treatment of moderate-to-severe plaque psoriasis in adults, along with the value of patient assistance/affordability programs.

A panel designs a conceptual framework in an effort to limit partiality.

The conference hosts a diversity, equity, and inclusion (DE&I) Summit featuring personal insights and experiences.

The seminar examines where members of the pharma supply chain stand in terms of preparation, being that the act has officially been enacted.

Session discusses ways to integrate digital pharmacies and hubs.

Panel uncovers ways to handle the increasing complexities and risks surrounding commercialization.